

Boris Juelg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4639930/publications.pdf>

Version: 2024-02-01

66
papers

4,444
citations

168829

31
h-index

134545

62
g-index

71
all docs

71
docs citations

71
times ranked

8950
citing authors

#	ARTICLE	IF	CITATIONS
1	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. <i>Immunity</i> , 2022, 55, 355-365.e4.	6.6	76
2	Landscape of Human Immunodeficiency Virus Neutralization Susceptibilities Across Tissue Reservoirs. <i>Clinical Infectious Diseases</i> , 2022, 75, 1342-1350.	2.9	4
3	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. <i>Nature Medicine</i> , 2022, 28, 1288-1296.	15.2	44
4	Broadly neutralizing antibodies for HIV-1 prevention and therapy. <i>Seminars in Immunology</i> , 2021, 51, 101475.	2.7	28
5	Antibodies for Human Immunodeficiency Virus-1 Cure Strategies. <i>Journal of Infectious Diseases</i> , 2021, 223, S22-S31.	1.9	7
6	Discrete SARS-CoV-2 antibody titers track with functional humoral stability. <i>Nature Communications</i> , 2021, 12, 1018.	5.8	82
7	Humoral signatures of protective and pathological SARS-CoV-2 infection in children. <i>Nature Medicine</i> , 2021, 27, 454-462.	15.2	137
8	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1535.	3.8	260
9	Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features. <i>MBio</i> , 2021, 12, .	1.8	10
10	Learning from HIV-1 to predict the immunogenicity of T _H cell epitopes in SARS-CoV-2. <i>IScience</i> , 2021, 24, 102311.	1.9	11
11	Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. <i>ELife</i> , 2021, 10, .	2.8	16
12	Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells. <i>Cell Reports</i> , 2021, 35, 109167.	2.9	8
13	Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 1184-1195.	13.9	371
14	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. <i>Science Immunology</i> , 2021, 6, eabj2901.	5.6	67
15	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. <i>JCI Insight</i> , 2021, 6, .	2.3	34
16	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nature Medicine</i> , 2021, 27, 1718-1724.	15.2	39
17	Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. <i>Nature Communications</i> , 2021, 12, 6853.	5.8	41
18	US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab563.	0.4	12

#	ARTICLE	IF	CITATIONS
19	Mining for humoral correlates of HIV control and latent reservoir size. PLoS Pathogens, 2020, 16, e1008868.	2.1	19
20	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. Cell Reports, 2020, 33, 108502.	2.9	19
21	Therapeutic Vaccines for the Treatment of HIV. Translational Research, 2020, 223, 61-75.	2.2	14
22	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. Cell Host and Microbe, 2019, 26, 336-346.e3.	5.1	88
23	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. Lancet HIV, 2019, 6, e259-e268.	2.1	139
24	Neutralizing antibodies for HIV-1 prevention. Current Opinion in HIV and AIDS, 2019, 14, 318-324.	1.5	34
25	Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. JCI Insight, 2019, 4, .	2.3	25
26	HIV Cure Strategies. , 2019, , 59-66.		0
27	Lymph node fibrosis: a structural barrier to unleashing effective vaccine immunity. Journal of Clinical Investigation, 2018, 128, 2743-2745.	3.9	4
28	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. Journal of Virology, 2017, 91, .	1.5	40
29	HIV-1 Latency by Transition. Immunity, 2017, 47, 611-612.	6.6	1
30	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Science Translational Medicine, 2017, 9, .	5.8	106
31	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science Translational Medicine, 2017, 9, .	5.8	87
32	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. Journal of Virology, 2017, 91, .	1.5	38
33	Broadly Neutralizing Antibodies: Magic Bullets against HIV?. Immunity, 2016, 44, 1253-1254.	6.6	3
34	HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature, 2016, 535, 556-560.	18.7	400
35	Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Research, 2016, 44, 5615-5628.	6.5	612
36	Novel immunological strategies for HIV-1 eradication. Journal of Virus Eradication, 2015, 1, 232-236.	0.3	6

#	ARTICLE	IF	CITATIONS
37	High Avidity CD8+ T Cells Efficiently Eliminate Motile HIV-Infected Targets and Execute a Locally Focused Program of Anti-Viral Function. PLoS ONE, 2014, 9, e87873.	1.1	31
38	Limited HIV Infection of Central Memory and Stem Cell Memory CD4+ T Cells Is Associated with Lack of Progression in Viremic Individuals. PLoS Pathogens, 2014, 10, e1004345.	2.1	76
39	Lack of Association between HLA Class II Alleles and <i>In Vitro</i> Replication Capacities of Recombinant Viruses Encoding HIV-1 Subtype C Gag-Protease from Chronically Infected Individuals. Journal of Virology, 2012, 86, 1273-1276.	1.5	8
40	Association of interleukin-10 promoter genetic variants with T-cell and B-cell activation in HIV-1 infection. Retrovirology, 2012, 9, .	0.9	0
41	Factors Predicting Discordant Virological and Immunological Responses to Antiretroviral Therapy in HIV-1 Clade C Infected Zulu/Xhosa in South Africa. PLoS ONE, 2012, 7, e31161.	1.1	20
42	HIV-1-Specific Interleukin-21 ⁺ CD4 ⁺ T Cell Responses Contribute to Durable Viral Control through the Modulation of HIV-Specific CD8 ⁺ T Cell Function. Journal of Virology, 2011, 85, 733-741.	1.5	173
43	Epithelial adhesion molecules can inhibit HIV-1-specific CD8+ T-cell functions. Blood, 2011, 117, 5112-5122.	0.6	31
44	Possession of HLA Class II DRB1*1303 Associates with Reduced Viral Loads in Chronic HIV-1 Clade C and B Infection. Journal of Infectious Diseases, 2011, 203, 803-809.	1.9	43
45	A high-throughput single-cell analysis of human CD8+ T cell functions reveals discordance for cytokine secretion and cytolysis. Journal of Clinical Investigation, 2011, 121, 4322-4331.	3.9	140
46	Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nature Medicine, 2010, 16, 1147-1151.	15.2	448
47	Infrequent Recovery of HIV from but Robust Exogenous Infection of Activated CD4 ⁺ T Cells in HIV Elite Controllers. Clinical Infectious Diseases, 2010, 51, 233-238.	2.9	98
48	Enhanced Anti-HIV Functional Activity Associated with Gag-Specific CD8 T-Cell Responses. Journal of Virology, 2010, 84, 5540-5549.	1.5	91
49	Differential Neutralization of Human Immunodeficiency Virus (HIV) Replication in Autologous CD4 T Cells by HIV-Specific Cytotoxic T Lymphocytes. Journal of Virology, 2009, 83, 3138-3149.	1.5	80
50	Impact of Select Immunologic and Virologic Biomarkers on CD4 Cell Count Decrease in Patients with Chronic HIV-1 Subtype C Infection: Results from Sinikithemba Cohort, Durban, South Africa. Clinical Infectious Diseases, 2009, 49, 956-964.	2.9	19
51	The Paradox of Incomplete CD4+Cell Count Restoration Despite Successful Antiretroviral Treatment and the Need to Start Highly Active Antiretroviral Therapy Early. Clinical Infectious Diseases, 2009, 48, 795-797.	2.9	8
52	Lack of Duffy Antigen Receptor for Chemokines: No Influence on HIV Disease Progression in an African Treatment-Naive Population. Cell Host and Microbe, 2009, 5, 413-415.	5.1	37
53	The Duffy Antigen Receptor for Chemokines Null Promoter Variant Does Not Influence HIV-1 Acquisition or Disease Progression. Cell Host and Microbe, 2009, 5, 408-410.	5.1	43
54	S04-06 OA. Polyvalent Gag-specific CD8 T-cells with enhanced functional properties are enriched in HIV-1 clade C infected individuals with lower viral loads. Retrovirology, 2009, 6, .	0.9	0

#	ARTICLE	IF	CITATIONS
55	Integrative Genomic Analysis of HIV-Specific CD8+ T Cells Reveals That PD-1 Inhibits T Cell Function by Upregulating the AP-1 Transcription Factor BATF.. Blood, 2009, 114, 916-916.	0.6	0
56	Bat-Associated Histoplasmosis Can Be Transmitted at Entrances of Bat Caves and Not Only Inside the Caves. Journal of Travel Medicine, 2008, 15, 133-136.	1.4	38
57	Severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir: case report. Aids, 2006, 20, 1563.	1.0	10
58	Pulmonary manifestation of a Langerhans cell sarcoma: case report and review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 369-374.	1.4	37
59	Treatment Interruption in HIV Therapy: a SMART Strategy?. Infection, 2006, 34, 186-188.	2.3	18
60	Clinical News from the XVI International AIDS Conference: The Attempt of a Summing up. Infection, 2006, 34, 294-297.	2.3	1
61	Nephrotic-Range Proteinuria Following Pamidronate Therapy in a Patient With Metastatic Breast Cancer: Mitochondrial Toxicity as a Pathogenetic Concept?. American Journal of Kidney Diseases, 2006, 47, 1075-1080.	2.1	37
62	Susceptibility to HIV/AIDS: An Individual Characteristic We Can Measure?. Infection, 2005, 33, 160-162.	2.3	13
63	HIV Genetic Diversity: Any Implications for Drug Resistance?. Infection, 2005, 33, 299-301.	2.3	17
64	What's New in HIV/AIDS? Neutralizing HIV Antibodies: Do they Really Protect?. Infection, 2005, 33, 405-407.	2.3	2
65	What's New in HIV/AIDS? Chemokine Receptor Antagonists: A New Era of HIV Therapy?. Infection, 2005, 33, 408-410.	2.3	2
66	Progression of renal impairment under therapy with tenofovir. Aids, 2005, 19, 1332-1333.	1.0	17